Financial Performance - Kingstone's core direct written premium grew by 17% compared to Q2 2024[6] - Net investment income increased by 30% compared to Q2 2024, with an average portfolio yield of 393%[6] - The company's combined ratio improved to 715% in Q2 2025, compared to 782% in Q2 2024[70] - Adjusted EBITDA increased by 884% to $14783 thousand in Q2 2025, compared to $7845 thousand in Q2 2024[70] - Net income rose by 1492% to $11252 thousand in Q2 2025, compared to $4515 thousand in Q2 2024[70] Strategic Initiatives - Kingstone's "Select" product has a ~31% lower frequency than the "Legacy" product, indicating improved risk selection[18] - Select policies represent 48% of policies in force as of June 30, 2025[18] - The company achieved a NY growth of +31% in FY2024[49] - Kingstone estimates approximately $12 million in premiums from the AmGuard renewal rights transaction, beginning September 1, 2025[47] Future Outlook - Kingstone anticipates net premiums earned of ~$187 million for fiscal year 2025[51] - The company aims to reach ~$500 million in direct premiums written by 2029[57]

Financial Performance - AQN's Net Earnings decreased by 90% to $17.4 million, compared to $180.1 million in the same period of the previous year[24] - AQN Adjusted Net Earnings decreased by 13% to $36.2 million, compared to $41.5 million in the same period of the previous year[24] - Adjusted Net Earnings per share decreased by 33% to $0.04, compared to $0.06 in the same period of the previous year[24] - Dividends per share declared to common shareholders decreased by 40% to $0.0650, compared to $0.1085 in the same period of the previous year[24] Rate Case Updates - BELCO was authorized an increase of $33.6 million out of a rate request of $59.1 million, implemented retroactively to Jan 1, 2024[38] - Granite State Electric was authorized an increase of $5.5 million out of a rate request of $15.5 million, implemented on April 1, 2025[38] - Midstates Gas in Missouri was authorized an increase of $9.1 million out of a rate request of $13.2 million, implemented on Jan 8, 2025[38] - Missouri Water was authorized an increase of $6.2 million out of a rate request of $8.1 million, implemented on Mar 1, 2025[38] - Various Water & Wastewater in Arizona was authorized an increase of $4.2 million out of a rate request of $6.0 million, implemented on July 1, 2025[38] Key Credit Adjustment Figures - S&P and Fitch selected debt adjustments include a deduction of $700 million for equity credit (50% of $1.4 billion hybrids) and $300 million for Empire securitization, with an addition of $90 million for preferred equity (50% of $180 million)[34] - Q2 debt stands at $6.3 billion[34]

Financial Performance - Adjusted EPS for Q2 2025 was $1.04, a 21% increase compared to $0.86 in Q2 2024[16, 24] - Adjusted Gross Margin for Q2 2025 reached $142.8 million, up 13% from Q2 2024[24] - Adjusted Net Income for Q2 2025 was $24.3 million, a 26% increase from Q2 2024[24] - Year-to-date Adjusted EPS reached $3.25, a 10% increase from YTD 2024[21, 25] - Year-to-date Adjusted Gross Margin was $325.2 million, up 12% from YTD 2024[25] - Year-to-date Adjusted Net Income was $75.4 million, a 14% increase from YTD 2024[25] Capital Expenditure and Projects - The company increased its 2025 capital expenditure guidance by $50 million, with a new range of $375 million to $425 million[17, 30] - A new Ohio pipeline project, with a capital investment of $10 million, will serve a fuel cell powering a data center and is expected to be operational in the first half of 2027[17, 44] - The Worcester Resiliency Upgrade (WRU) project, a $100 million FERC-approved LNG storage facility, is expected to add $3.9 million of additional full-year margin[46, 49, 50] Regulatory and Strategic Initiatives - Final orders were received for all three active rate cases in Delaware, Maryland, and Florida[17] - The company reaffirmed its 2025 Adjusted EPS guidance range of $6.15 to $6.35[30]

Financial Performance - The company generated Q2 2025 net revenue of $37.2 million and year-to-date 2025 net revenue of $76.1 million[9] - Acute Care franchise revenue grew by 55.5% for the three months ended June 30, 2025, compared to the same period last year[9] - The company achieved a record year-to-date 2025 adjusted EBITDA of $7.9 million[9] - Net product sales for Q2 2025 were $37.2 million, compared to $36.024 million in Q2 2024[32] - Adjusted EBITDA for Q2 2025 was $1.771 million, compared to $(1.234) million in Q2 2024[34] Product Performance - ZYNRELEF unit demand grew by 6.3% in Q2 2025 compared to Q1 2025[9] - APONVIE unit demand grew by 19% in Q2 2025 compared to Q1 2025[9] - Acute Care franchise net sales were $10.7 million for the three months ended June 30, 2025[14] - Oncology Care franchise net sales were $26.5 million for the three months ended June 30, 2025[26] Refinancing and Capital Structure - The company completed a comprehensive refinancing of prior debt facilities, reducing total debt from $175 million to $145 million and extending the bullet maturity to 2030+[9] - $110 million was funded at closing from Hercules Capital as a senior secured term loan[38] - $35 million of 50% Senior Convertible Notes were issued to Rubric Capital Management due in 2031[38]

Financial Performance - Revenue for Q2 2025 increased by 896% year-over-year to $3146 million from $1660 million in Q2 2024[52, 55] - Genomics revenue reached $2418 million, a 1153% increase compared to Q2 2024[55] - Data and Services revenue totaled $728 million, growing 357% year-over-year, with Insights (data licensing) growing 407%[55] - Gross profit improved by 1583% year-over-year, reaching $1950 million in Q2 2025[52, 55] - Adjusted EBITDA improved by 821%, with a loss of $(56) million in Q2 2025 compared to $(312) million in Q2 2024[52, 55] Genomics Business - Oncology testing (Tempus Genomics) revenue was $1332 million, up 329% year-over-year, with approximately 26% volume growth[55] - Hereditary testing (Ambry Genetics) contributed $973 million of revenue, up 336% year-over-year on a pro forma basis, with approximately 32% volume growth[55] - Average reimbursement per hereditary test was $760 in Q2 2025[24] Data and AI - Total Remaining Contract Value for Data and Services was >$940 million at the end of 2024[39] - Data Licensing Retention was ~140% at the end of 2024[39] - Tempus has >350 petabytes of rich multimodal healthcare data[12, 37]

Company Overview - China Yuchai International Limited (CYD) holds a 76.4% equity interest in Guangxi Yuchai Machinery Company Limited (GYMCL)[9] - Yuchai has a total engine production capacity of 600,000 units per annum[11] - Yuchai has over 3,000 domestic service stations throughout China[11] Market and Sales - China's GDP is targeted to grow approximately 5% for 2025[20] - In 2024, commercial vehicle industry unit sales reached 1 million, a YoY decrease of 9.9%[20] - In 2024, total truck sales increased by 15% YoY, with the HD segment accounting for 43% of total truck sales[24] - In 2024, total bus sales approximated 300,000 units, an increase of 28% YoY[24] - China Yuchai's total unit sales in 2024 (excluding NEV) were 344,486 units[31] Financial Performance - In 2024, the company's revenue reached RMB 19.1 billion[128] - The gross profit percentage in 2024 was 14.7%[136] - The profit after tax in 2024 was RMB 0.5 billion[136] - As of 2024, the company's cash and bank balance was RMB 6.4 billion[137] - In 2024, a share buyback was conducted for approximately US$ 39.8 million[142]

AUGUST 2025 Investor Presentation Note: All financials presented are in US$ unless otherwise noted. Disclaimer General This presentation is property of Docebo Inc. (the "Company", "Docebo", "us" or "we"). It cannot be circulated or forwarded without our consent. Any graphs, tables or other information demonstrating our historical performance or that of any other entity contained in this presentation are intended only to illustrate past performance and are not necessarily indicative of our or such entities' ...

Financial Performance - The estimated combined risk-based capital (RBC) ratio is between 405% and 425%[9, 32] - The holding company liquid assets are $0.9 billion[9, 31] - The statutory combined total adjusted capital (TAC) is $5.6 billion[9] - The year-to-date normalized statutory loss is $0.1 billion[9] - Adjusted earnings were $198 million, $60 million below expectations, primarily due to a lower alternative investment income yield of 1.5%[9] Segment Performance - Annuities adjusted earnings, less notable items, were $332 million, an increase of 8% compared to 2Q 2024[12, 69] - Life Insurance adjusted earnings, less notable items, were $(26) million[17, 69] - Run-off adjusted earnings (loss), less notable items, were $(83) million[23, 69] - Corporate & Other adjusted earnings (loss), less notable items, were $(25) million[25, 69] Investment Portfolio - Total investments are $127 billion[36] - Fixed maturity securities (FMS) are $87 billion, with 97% investment grade[36] - Commercial mortgage loan portfolio is $12.9 billion, representing 10% of total investments[40]

Second Quarter 2025 Earnings Presentation August 8, 2025 Forward Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that these expectati ...

Financial Highlights - Adjusted operating income was $50 million, or $1.01 per share, for the second quarter of 2025[9] - The company insured $10 billion of new business par in the second quarter of 2025, the largest second-quarter amount in a decade[9] - The company generated $64 million of new business production (PVP) in the second quarter of 2025[9] - Pretax adjusted operating income from asset management was $5 million in the second quarter of 2025[9] - Pretax adjusted operating income from the alternative investment portfolio was $16 million in the second quarter of 2025[9] - Capital returned to shareholders in the second quarter of 2025 was $150 million, including share repurchases of $131 million (1.5 million shares) and dividends of $19 million[9] - Adjusted operating income was $212 million, or $4.21 per share, in the first half of 2025, a 23% increase compared to the first half of 2024[11] - The company insured $15 billion of new business par in the first half of 2025, the largest amount of first-half par insured in a decade[15] - The company generated $103 million of PVP in the first half of 2025[15] - The company repurchased nearly 3 million shares at a total cost of $251 million in the first half of 2025, representing nearly 6% of shares outstanding on December 31, 2024[15]